Drugs that contain Lacosamide
1. Motpoly Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11337943 | AUCTA | Lacosamide pharmaceutical composition and dosage form thereof |
Jun, 2040
(16 years from now) | |
Market Authorisation Date: 04 May, 2023
Treatment: Treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
More Information on Dosage
MOTPOLY XR family patents
2. Vimpat patents expiration
VIMPAT Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5654301 | UCB INC | Amino acid derivative anticonvulsant |
Aug, 2014
(9 years ago) | |
| USRE38551 | UCB INC | Anticonvulsant enantiomeric amino acid derivatives |
Mar, 2022
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-188) | Apr 28, 2026 |
| New Patient Population(NPP) | Oct 14, 2024 |
| New Dosing Schedule(D-144) | Aug 29, 2017 |
| New Indication(I-696) | Aug 29, 2017 |
| New Dosing Schedule(D-143) | Aug 29, 2017 |
| New Indication(I-878) | Nov 16, 2023 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2013 |
NCE-1 date: 28 October, 2012
Market Authorisation Date: 28 October, 2008
Treatment: Method of treating, as adjunctive therapy, partial-onset seizures in a patient with epilepsy aged 17 years and older; Method of treating, as monotherapy or adjunctive therapy, partial-onset seizures i...
Dosage: TABLET;ORAL; SOLUTION;ORAL; SOLUTION;INTRAVENOUS
How can I launch a generic of VIMPAT before it's drug patent expiration?
More Information on Dosage
VIMPAT family patents